ProCE Banner Activity


Individualizing Management in T2D With CKD


In this microlearning module, an expert faculty provides an overview of the considerations for management of CKD associated with T2D, with a focus on pharmacotherapy options.

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Nurses: 0.25 Nursing contact hour

Released: September 21, 2022

Expiration: September 20, 2023

No longer available for credit.



Vivian A. Fonseca

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences center
New Orleans, Louisiana

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


This activity is supported by independent educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Boehringer Ingelheim and Eli Lilly

Target Audience

This program is intended for nephrologists, endocrinologists, primary care physicians, and specialty and primary care advanced practice providers (nurse practitioner/physician assistant).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply treatment strategies to improve renal and CV outcomes in patients with T2D and CKD based on AEs, patient-specific factors, and preferences


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences center
New Orleans, Louisiana

Vivian A. Fonseca, MD, FRCP: consultant: Abbott, Asahi, AstraZeneca, Bayer, Novo Nordisk, Sanofi; researcher (paid to institution): Fractyl, Jaguar Gene Therapy; stock/stock options: Amgen, Abbott, Bravo4Health

Staff Disclosure


Robin Black, PharmD, BCACP

Scientific Director

Robin Black, PharmD, BCACP, has no relevant financial relationships to disclose.

Ruth Cohen,

Ruth Cohen Cooper, CHCP, has no relevant financial relationships to disclose.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 21, 2022, through September 20, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.



The goal of this activity is to improve healthcare professionals’ competence in the management of T2D-associated CKD, including the clinical evidence, place in therapy, and optimization of medication regimens for patients with CKD receiving an SGLT2 inhibitor and/or finerenone.